- STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefitOn analyses that looked at major cardiovascular events, those taking retatrutide did not have a significant lower risk of death, heart attack, or stroke.STAT · 1d ago↗ source
- Exclusive: Obesity biotech Verdiva hires ex-Metsera CMO as crucial readouts nearLong-acting obesity pill developer Verdiva Bio has a new chief medical officer, and he comes from a biotech that was looking at very similar technology — and got bought for $10 billion not long ago…Endpoints · 1d ago↗ source
- Scancell to go public after winning reverse merger bid for troubled NeuphoriaScancell and Neuphoria have made their union official via a reverse merger that will result in a Nasdaq listing for Scancell and a resolution for Neuphoria’s shareholders after the biotech ended it…